From new data released at AAIC 2023, here's what's different about Alzheon’s experimental Alzheimer's pill, ALZ-801.
Drugmaker Alzheon is currently running clinical trials on a new disease-modifying Alzheimer’s treatment: valiltramiprosate, or ALZ-801. While, like the new buzzy new Alzheimer’s monoclonal antibodies Leqembi and Aduhelm, it’s also designed to target amyloid proteins in the brain, it’s a little bit different — in some very important ways. And the drugmakers predict it may be just two years before it becomes widely available to people living with Alzheimer’s disease.
